8-K: Medtronic Q2 FY26 Beats Estimates, Raises Full-Year Outlook

Medtronic plc reported strong second quarter fiscal year 2026 financial results, exceeding revenue and EPS expectations and raising its full-year guidance.

Summary

• Q2 FY26 revenue reached $9.0 billion, a 6.6% increase as reported and 5.5% organically, surpassing guidance by 75 basis points.
• GAAP diluted EPS was $1.07, up 8%, and non-GAAP diluted EPS was $1.36, also up 8%, both exceeding expectations.
• The company raised its full-year FY26 organic revenue growth guidance to approximately 5.5% from 5.0%.
• Full-year FY26 diluted non-GAAP EPS guidance was raised to a range of $5.62 to $5.66, up from the prior $5.60 to $5.66.
• Cardiovascular Portfolio revenue grew 10.8% reported and 9.3% organically, marking its strongest growth in over a decade (excluding pandemic impact).
• Cardiac Ablation Solutions revenue surged 71%, including 128% in the U.S., driven by the pulsed field ablation (PFA) portfolio.
• Received broad, favorable U.S. CMS National Coverage Determination and commercial payer coverage for the Symplicity procedure for uncontrolled hypertension, targeting an 18 million-person U.S. market.
• Secured U.S. FDA approval for the Altaviva device for urge urinary incontinence, affecting over 16 million people in the U.S.
• The Hugo robotic-assisted surgery system's Enable Hernia Repair study met safety and effectiveness endpoints, and the Embrace Gynecology US pivotal study was initiated.
• U.S. FDA cleared the MiniMed 780G system for integration with the Instinct sensor and approved its use in Type 2 diabetes.

Sentiment

Score: 8

Explanation: The company reported strong financial results, beating both revenue and EPS expectations, and subsequently raised its full-year guidance. Significant growth drivers, particularly in Cardiovascular with PFA and Symplicity, received favorable regulatory and coverage decisions, indicating strong market momentum. While operating margins saw a slight decrease and some segments showed flat growth, the overall outlook is positive due to strategic investments and product pipeline strength.

Positives

• Q2 FY26 revenue of $9.0 billion exceeded expectations, growing 6.6% reported and 5.5% organically, 75 basis points above guidance midpoint.
• GAAP diluted EPS of $1.07 and non-GAAP diluted EPS of $1.36 both increased 8%, surpassing guidance.
• Full-year FY26 organic revenue growth guidance raised to approximately 5.5% from 5.0%.
• Full-year FY26 diluted non-GAAP EPS guidance raised to $5.62-$5.66 from $5.60-$5.66.
• Strongest Cardiovascular revenue growth in over a decade, excluding pandemic, with 9.3% organic growth.
• Cardiac Ablation Solutions revenue grew 71% globally and 128% in the U.S., driven by the pulsed field ablation (PFA) portfolio.
• Favorable National Coverage Determination from U.S. CMS and commercial payer coverage for the Symplicity procedure for hypertension, addressing a U.S. market of 18 million people.
• U.S. FDA approval for the Altaviva device for urge urinary incontinence, impacting over 16 million people in the U.S.
• Hugo robotic-assisted surgery system's Enable Hernia Repair study met safety and effectiveness endpoints.
• U.S. FDA cleared MiniMed 780G system for Instinct sensor integration and approved for Type 2 diabetes.
• Underlying efficiency gains in gross margin and increased R&D investment.

Negatives

• GAAP and non-GAAP operating margins both decreased by 20 basis points in Q2 FY26 compared to Q2 FY25.
• Specialty Therapies segment showed flat organic growth (0.3%) in Q2 FY26.
• Medical Surgical Portfolio had relatively lower organic growth at 1.3% in Q2 FY26.
• U.S. Diabetes business revenue decreased by 0.8% reported and organically in Q2 FY26.
• U.S. Surgical & Endoscopy revenue decreased by 1.5% reported and organically in Q2 FY26.
• U.S. Specialty Therapies revenue decreased by 2.2% reported and organically in Q2 FY26.

Risks

• Competitive factors in the medical device industry.
• Difficulties and delays inherent in the development, manufacturing, marketing, and sale of medical products.
• Impact of government regulation on product approvals and market access.
• Geopolitical conflicts and their potential disruption to operations and supply chains.
• Changes in global trade policies, including tariffs, which could impact costs and profitability (e.g., potential $185 million impact from tariffs mentioned in guidance).
• Risks associated with material acquisition and divestiture transactions.
• General economic conditions affecting healthcare spending and patient volumes.
• Other risks and uncertainties detailed in the company's periodic reports on file with the U.S. Securities and Exchange Commission, including the most recent Annual Report on Form 10-K.

Future Outlook

Medtronic raised its full-year fiscal year 2026 organic revenue growth guidance to approximately 5.5% and its diluted non-GAAP EPS guidance to a range of $5.62 to $5.66. The company anticipates even greater acceleration of revenue growth in the back half of the year and beyond, driven by key enterprise growth drivers such as the PFA franchise for Afib, Symplicity procedure for hypertension, Hugo robotic-assisted surgery system, and Altaviva therapy for urge urinary incontinence.

Management Comments

• "We delivered a strong second quarter, with both revenue and EPS beating expectations. Overall, procedure volumes and our end markets are robust, and were executing well across the business." Geoff Martha, Chairman and CEO.
• "Looking ahead, we are positioned for even greater acceleration of revenue growth in the back half of the year and beyond, driven by several enterprise growth drivers, including our PFA franchise for Afib, Symplicity procedure for hypertension, Hugo robotic-assisted surgery system, and Altaviva therapy for urge urinary incontinence." Geoff Martha, Chairman and CEO.
• "In the second quarter, we drove underlying efficiency gains in our gross margin, significantly increased R&D to fuel our future growth, as well as strategically increased investment in sales and marketing for our growth programs in light of the outsized demand and building momentum for key programs." Thierry Piton, Chief Financial Officer.
• "Given our outperformance in the first half of the year and confidence we have in our revenue growth acceleration, we are raising today our full year revenue and EPS guidance." Thierry Piton, Chief Financial Officer.

Industry Context

Medtronic's strong performance, particularly in Cardiovascular and Diabetes, and the acceleration of key growth drivers like PFA and Symplicity, suggest a robust demand environment for innovative medical technologies. The favorable CMS coverage for Symplicity and FDA approvals for Altaviva and MiniMed 780G indicate a positive regulatory landscape and successful product development, positioning Medtronic to capitalize on significant unmet medical needs in large patient populations. The increased R&D and sales & marketing investments reflect a strategic push to capture market share in high-growth segments, aligning with broader industry trends of innovation-driven expansion.

Comparison to Industry Standards

• The filing does not provide specific comparable company or project data to assess against global benchmarks. However, the reported 71% growth in Cardiac Ablation Solutions, including 128% in the U.S., driven by the pulsed field ablation (PFA) portfolio, is an exceptionally high growth rate for a mature medical device segment, suggesting strong market adoption and competitive advantage for Medtronic's PFA technology.
• The broad favorable National Coverage Determination from U.S. CMS for the Symplicity procedure for hypertension, addressing an 18 million-person market, indicates a significant market opportunity that could set a new standard for non-pharmacological hypertension management, potentially outperforming existing or emerging solutions from competitors in this space.

Legal Proceedings

• Adjustments to the Company's Italian payback accruals resulting from two July 22, 2024 rulings by the Constitutional Court and a Legislative Decree published by the Italian government on June 30, 2025, for certain prior years since 2015.
• Certain litigation charges, net, of $27 million for Q2 FY26 and $81 million for the six months ended October 24, 2025.

Stakeholder Impact

• Shareholders/Investors: Positive impact due to strong financial performance, raised guidance, and acceleration of key growth drivers, potentially leading to increased share value.
• Customers (Patients/Healthcare Providers): Positive impact from new product approvals (Altaviva, MiniMed 780G, Symplicity coverage) offering innovative solutions for various health conditions.
• Employees: Continued focus on innovation and growth may provide stability and opportunities, though restructuring charges are mentioned as a non-GAAP adjustment.
• Regulatory Authorities: Continued engagement with FDA and CMS for product approvals and coverage decisions.

Next Steps

• Continue execution across the business to achieve greater acceleration of revenue growth in the back half of FY26 and beyond.
• Drive enterprise growth drivers including the PFA franchise for Afib, Symplicity procedure for hypertension, Hugo robotic-assisted surgery system, and Altaviva therapy for urge urinary incontinence.
• Host a video webcast on November 18, 2025, at 8:00 a.m. EST to provide information about business for the public, investors, analysts, and news media.

Key Dates

Recommendation

Medtronic delivered a robust second quarter, significantly outperforming revenue and EPS expectations, which led to an upward revision of its full-year guidance. The company is demonstrating strong momentum in critical growth areas, particularly with its Cardiac Ablation Solutions (71% growth) and the Symplicity procedure for hypertension, which secured broad U.S. CMS coverage for a large addressable market. Recent FDA approvals for Altaviva and MiniMed 780G further strengthen its product pipeline and market reach. Strategic investments in R&D and sales & marketing are fueling future growth, indicating a well-managed strategy to capitalize on innovation. Despite a slight dip in operating margins, the overall trajectory and execution on key initiatives make Medtronic a compelling 'strong buy' for long-term investors seeking exposure to a leading, innovative healthcare technology company.

Keywords

Medtronic, MDT, financial results, Q2 FY26, earnings, revenue, EPS, guidance, medical devices, healthcare technology, Cardiovascular, Cardiac Ablation Solutions, Pulsed Field Ablation, PFA, Symplicity procedure, hypertension, FDA approval, Altaviva device, urinary incontinence, Hugo robotic-assisted surgery, MiniMed 780G, diabetes, Neuroscience, Medical Surgical